MCAS Diagnostic Criteria: Symptoms, Tryptase, and Diagnostic Limits

Why a broad symptom list or one baseline tryptase value is not enough — and how consensus criteria protect patients from both dismissal and overdiagnosis

William Love, MD, FMCP-M | Board-Certified Internal Medicine | Love Functional Medicine

Consensus MCAS diagnosis generally requires recurrent systemic symptoms involving at least two organ systems, an objective event-related rise in a validated mast-cell mediator, and improvement with mediator-targeted treatment. A broad symptom list or one baseline tryptase value is not sufficient.

Mast cells participate in allergic responses and release mediators capable of affecting multiple organ systems. That biology is real. The diagnostic problem is that flushing, itching, gastrointestinal symptoms, tachycardia, dizziness, headache, and fatigue are common and nonspecific. A list of compatible symptoms can raise a question; it cannot establish mast-cell activation syndrome.

The consensus framework

Consensus criteria for MCAS generally require three elements: recurrent, episodic symptoms consistent with systemic mast-cell mediator release involving at least two organ systems; objective evidence of mediator release during an event; and a clinically meaningful response to treatment directed at mast-cell mediators. Other explanations must also be considered.

Tryptase: baseline and event are different measurements

A normal baseline tryptase does not by itself rule out an acute mast-cell activation event. The relevant comparison is an appropriately timed acute value against the patient's baseline after recovery. The widely used consensus threshold is an acute rise exceeding baseline multiplied by 1.2, plus 2 ng/mL. Timing matters because tryptase rises and falls over hours.

A persistently elevated baseline tryptase raises a different set of questions, including hereditary alpha-tryptasemia, systemic mastocytosis, renal disease, or other hematologic conditions. It is not synonymous with MCAS.

Other mediator tests

Urinary histamine metabolites, prostaglandin metabolites, and leukotriene E4 may be used in selected cases, but preanalytic conditions, timing, laboratory methods, diet, medications, and incomplete validation complicate interpretation. An isolated result should not carry the weight of a diagnosis without a compatible episode and differential.

Why discipline matters

Underdiagnosis can leave severe episodic reactions unexplained. Overdiagnosis can attach a broad label to nonspecific symptoms, drive restrictive diets and extensive testing, and delay consideration of allergic, gastrointestinal, endocrine, cardiovascular, autonomic, hematologic, or psychological explanations. Consensus criteria are not barriers to listening. They are safeguards against turning plausibility into certainty.

When care is urgent

Symptoms of anaphylaxis — including airway compromise, significant breathing difficulty, hypotension, or rapidly progressive multisystem reactions — require emergency care. An educational article or outpatient consultation is not an alternative to acute treatment.

Related reading: Normal Labs but Still Feel Sick and Medically Unexplained Symptoms — Without Dismissal.

Questions readers commonly ask

What are the consensus criteria for MCAS?

The usual framework requires recurrent systemic symptoms affecting at least two organ systems, objective evidence of mediator release during an event, and response to mediator-targeted treatment.

What does the tryptase 20% + 2 formula mean?

An event-related tryptase must rise above the person's baseline by 20 percent plus 2 ng/mL. A single baseline value does not test that change.

Can normal tryptase exclude every mast-cell disorder?

No, but failure to document an accepted mediator rise means consensus MCAS criteria have not been met. Other diagnoses and testing limitations still require consideration.

Selected references

Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125–1133.

Valent P, Akin C, Bonadonna P, et al. Mast cell activation syndrome: importance of consensus criteria and call for research. J Allergy Clin Immunol. 2018;142(3):1008–1010.

Weiler CR. Mast cell activation syndrome: tools for diagnosis and differential diagnosis. J Allergy Clin Immunol Pract. 2020;8(2):498–506.

About Love Functional Medicine

William Love, MD, FMCP-M, is board-certified in internal medicine with advanced training in functional medicine. Love Functional Medicine evaluates adults physically located in Pennsylvania and works alongside existing primary and specialty care. Adults physically located in Pennsylvania may request a consultation when a mast-cell question remains after appropriate evaluation. Allergy/immunology and hematology remain essential partners when indicated.

This practice does not provide urgent or emergency care. For urgent concerns, contact your primary care clinician; in an emergency, call 911 or go to the nearest emergency department.

Consultations are scheduled through Healthie, the practice's secure booking system.